<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02335593</url>
  </required_header>
  <id_info>
    <org_study_id>PHCL394</org_study_id>
    <nct_id>NCT02335593</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Zinc Supplementation on Anemia, Oxidative Stress and Inflammation in Hemodialysis Patients</brief_title>
  <official_title>Evaluation of the Effect of Zinc Supplementation on the Health Status of Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Urology and Nephrology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the effect of Zinc supplementation on health status
      of hemodialysis patients through measurement of the following before and after Zinc
      administration: Inflammatory markers, Oxidative stress markers and Anemia markers. Also,
      Evaluation of quality of life of hemodialysis patients before and after Zinc administration
      using Fatigue severity scale questionnaire.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect on Anemic status (Measurement of Hemoglobin, Hematocrit, serum iron,Total Iron Binding Capacity and serum ferritin)</measure>
    <time_frame>three months</time_frame>
    <description>at baseline and after 3 monthes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect on Oxidative stress (Measurement of Malondialdehyde, Total antioxidant capacity, Nitric oxide and Superoxide dismutase)</measure>
    <time_frame>three months</time_frame>
    <description>Measurement of Malondialdehyde, Total antioxidant capacity, Nitric oxide and Superoxide dismutase at baseline and after 3 monthes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on Inflammatory status. (Measurement of C-Reactive protein and Interleukin-6)</measure>
    <time_frame>three months</time_frame>
    <description>Measurement of C-Reactive protein and Interleukin-6 at baseline and after 3 monthes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect on Fatigue (Fatigue Sevrity Scale)</measure>
    <time_frame>three months</time_frame>
    <description>Using Fatigue Sevrity Scale at baseline and after 3 monthes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Zinc group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Zinc Sulphate Hard Gel Capsules 110 mg once daily for three months plus Epoetin alfa 2000-4000 IU solution for injection andIron Hydroxide Saccharate Complex Solution for injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Corn starch filled Hard Gel capsules once daily plus 'Epoetin alfa 2000-4000 IU solution for injection and Iron Hydroxide Saccharate Complex Solution for injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Zinc Sulphate</intervention_name>
    <description>Zinc Sulphate Hard Gel capsules 110mg</description>
    <arm_group_label>Zinc group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Corn Starch filled Hard Gel Capsules</intervention_name>
    <description>Corn Starch filled Hard Gel Capsules</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoetin alfa 2000-4000 IU solution for injection</intervention_name>
    <description>Epoetin alfa 2000-4000 IU solution for injection</description>
    <arm_group_label>Zinc group</arm_group_label>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron Hydroxide Saccharate Complex Solution for injection</intervention_name>
    <description>Iron Hydroxide Saccharate Complex Solution for injection</description>
    <arm_group_label>Zinc group</arm_group_label>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Under regular hemodialysis for at least 6 months.

          -  Clinically stable condition as outpatients.

          -  Zinc-deficient patients (plasma Zinc concentrations less than 80 mcg/dl).

        Exclusion Criteria:

          -  Patients taking any antioxidant supplements including vitamin E, Omega-3 fatty acids,
             green tea preparations or immunosuppressive medications within 2 months prior to
             enrollment in the study.

          -  Patients receiving Al hydroxide phosphate binders.

          -  Hospitalization in the previous month before the onset of the trial, or having active
             infection.

          -  Patients with malabsorption diseases (e.g, Crohn's disease), liver diseases, cancers,
             mental retardation, dementia or psychiatric illness.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rasha R. El-kady, Bachelor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmad M. Elseasi, Lecturer</last_name>
    <email>elsisiahmed@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Institute of Urology and Nephrology</name>
      <address>
        <city>Cairo</city>
        <state>El Matareya</state>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmad M. Elseasi, Lecturer</last_name>
      <email>elsisiahmed@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Rasha R. El-kady, Bachelor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 31, 2014</study_first_submitted>
  <study_first_submitted_qc>January 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2015</study_first_posted>
  <last_update_submitted>January 9, 2015</last_update_submitted>
  <last_update_submitted_qc>January 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Rasha Roshdy Ibrahim El-kady</investigator_full_name>
    <investigator_title>Teaching Assistant</investigator_title>
  </responsible_party>
  <keyword>Hemodialysis patients</keyword>
  <keyword>Zinc</keyword>
  <keyword>Anemia</keyword>
  <keyword>Oxidative stress</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Zinc</mesh_term>
    <mesh_term>Epoetin Alfa</mesh_term>
    <mesh_term>Zinc Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

